About EvoEndo
EvoEndo is a company based in Englewood (United States) founded in 2017 by Joel Friedlander. It operates as a HealthTech and Direct-to-Consumer (D2C). EvoEndo has raised $20.75 million across 4 funding rounds from investors including Gastro, Varia Ventures and TLP Investments. EvoEndo offers products and services including EvoEndo Endoscopy System and Ultra-Thin Endoscopes. EvoEndo operates in a competitive market with competitors including Auris Health, MedInTech, Karl Storz, Wooptix and Aohua Endoscopy, among others.
- Headquarter Englewood, United States
- Founders Joel Friedlander
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Evoendo, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20.75 M (USD)
in 4 rounds
-
Latest Funding Round
$2.25 M (USD), Series A
Aug 02, 2024
-
Investors
Gastro
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EvoEndo
EvoEndo offers a comprehensive portfolio of products and services, including EvoEndo Endoscopy System and Ultra-Thin Endoscopes.
Designed for sedation-free pediatric and adult endoscopy.
High-performance scopes for small anatomy endoscopy procedures.
People of EvoEndo
Unlock access to complete
Unlock access to complete
Funding Insights of EvoEndo
EvoEndo has successfully raised a total of $20.75M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $2.25 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EvoEndo
EvoEndo has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Gastro, Varia Ventures and TLP Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A gastroenterology organization is based in the United States.
|
Locked | Locked | Locked | |
|
Venture capital funds are managed by Varia Ventures.
|
Locked | Locked | Locked | |
|
Capital is invested by TLP Investments for economic and social impact.
|
Locked | Locked | Locked |
Investor details for EvoEndo
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EvoEndo
Investment portfolio details for EvoEndo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - EvoEndo
Detailed financials for EvoEndo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evoendo Comparisons
Peer comparison for EvoEndo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EvoEndo
EvoEndo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Auris Health, MedInTech, Karl Storz, Wooptix and Aohua Endoscopy, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Robotic microsurgical systems for endoscopy are developed.
|
|
| Locked | Locked | Locked |
Medical device technologies are developed with AI for diagnostics.
|
|
| Locked | Locked | Locked |
Endoscopic instruments, devices, and camera systems are developed and manufactured.
|
|
| Locked | Locked | Locked |
Application that allows 3D capture using single standard camera
|
|
| Locked | Locked | Locked |
Endoscopic devices and accessories are developed for medical use.
|
|
| Locked | Locked | Locked |
Endoscopic medical devices are designed and manufactured for surgical applications.
|
Detailed competitors of EvoEndo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evoendo
Complete news archive for EvoEndo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EvoEndo
EvoEndo was founded in 2017 and raised its 1st funding round 4 years after it was founded.
EvoEndo is headquartered in Englewood, United States. It is registered at Englewood, New Jersey, United States.
Jonathan Hartmann is the current CEO of EvoEndo.
EvoEndo is a funded company, having raised a total of $20.75M across 4 funding rounds to date.
EvoEndo is dedicated to providing innovative sedation-free endoscopy systems, primarily for pediatric and adult patients. The company offers the FDA-cleared EvoEndo Endoscopy System, designed for transnasal and transoral procedures without sedation. Solutions are developed to enhance patient experience by reducing risks and recovery time. The healthcare sector is served through advanced medical devices that align with evolving care standards, such as the 2025 ACG Guidelines for Eosinophilic Esophagitis (EoE).
EvoEndo's top competitors include Auris Health, Wooptix and UnivLabs.
EvoEndo offers EvoEndo Endoscopy System and Ultra-Thin Endoscopes.
EvoEndo has 3 investors. Key investors include Gastro, Varia Ventures, and TLP Investments.